Adagrasib has 5 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Drugs That Prolong Qtc Interval, Cyp3a Inducers, Mao Inhibitors. Patients taking Adagrasib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Contraindicated
- 1
- Major
- 4
Contraindicated (1)
- Adagrasib + Drugs That Prolong Qtc Interval— Concomitant use with KRAZATI is contraindicated.
Major (4)
- Adagrasib + Cyp3a Inducers— Concomitant use reduces adagrasib exposure, which may reduce the effectiveness of KRAZATI.
- Adagrasib + Mao Inhibitors— Concomitant use increases adagrasib concentrations before steady state, which may increase the risk of KRAZATI adverse r…
- Adagrasib + P-Gp Or Bcrp Substrates— Adagrasib increases exposure of P-gp substrates, which may increase the risk of adverse reactions where minimal concentr…
- Adagrasib + Sensitive Cyp3a Substrates— Adagrasib increases exposure of CYP3A4 substrates, which may increase the risk of adverse reactions related to these sub…